OncoTargets and Therapy (Jun 2020)
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Abstract
Innocenza Palaia,* Federica Tomao,* Carolina Maria Sassu, Lucia Musacchio, Pierluigi Benedetti Panici Department of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome, Policlinico Umberto I, Rome 00161, Italy*These authors contributed equally to this workCorrespondence: Innocenza PalaiaDepartment of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome, Policlinico Umberto I, Viale Del Policlinico 155, Rome 00161, ItalyTel +39064940550Email [email protected]: Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer. Although many advances have been made in therapeutic strategies, the global standard of care still remains radical surgery plus chemotherapy, but new scenarios need to be explored to improve survival. The role of immunotherapy in EOC treatment is controversial. Results obtained from studies evaluating immunotherapy are contradictory: in particular data on survival are not as good as expected when immunotherapy was administered alone, and other data are still immature. Thus, significant efforts must be devoted to finding new strategies for the use of immunotherapy. The aim of this paper is to review the most recent findings of the use of immunotherapy in ovarian cancer, with a particular focus on combination approaches.Keywords: immunotherapy, ovarian cancer, adoptive cell therapy, combination strategies, therapeutic vaccination, immune-checkpoint inhibitors
